BETHESDA, Md., Oct. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at two upcoming investor conferences; one sponsored by Natixis Bleichroeder, Inc. and the other by the Biotechnology Industry Organization (BIO).
Dr. Itin will present at the Natixis Bleichroeder Hidden Gems Conference in New York City, on Monday, October 8, 2007 at 4:15 p.m. Eastern time (10:15 p.m. central European time).
Dr. Itin will also present at the BIO InvestorForum conference in San Francisco, on Wednesday, October 10, 2007 at 4:45 p.m. local time (7:45 p.m. Eastern time/1:45 a.m. central European time on October 11th). In addition, Dr. Itin will be part of a panel titled "Turning Up the Heat on Cancer: New Technologies to Enhance Antibodies" at the BIO InvestorForum conference on Thursday, October 11, 2007 at 8:15 a.m. local time (11:15 a.m. Eastern time/5:15 p.m. central European time).
An audio webcast of Dr. Itin's remarks from both conferences will be available live and accessible through Micromet's website at http://www.micromet-inc.com. A replay and a download of the presentations will also be available via the website for approximately 2 weeks following the event.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases. Three product candidates are currently in clinical trials. MT103, also known as MEDI-538, is the first product candidate based on Micromet's novel BiTE(R) antibody product development platform and is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. The BiTE antibody product development platform is based on a unique, antibody-based class of drugs that leverages the cytotoxic potential of T cells in the treatment of cancer. T cells are the most powerful 'killer cells' of the human immune system. Micromet has established a collaboration with MedImmune, Astra Zeneca plc's wholly-owned subsidiary, for MT103/MEDI- 538. The second clinical stage product candidate is adecatumumab, also known as MT201, a recombinant human monoclonal antibody which targets EpCAM expressing tumors. Adecatumumab is being developed for the treatment of patients with breast cancer. A phase 2a clinical trial in this indication has been completed and a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Our third clinical stage product candidate is MT293, also known as TRC093 (and formerly D93), a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. This product candidate is in phase 1 clinical trials and is being developed by TRACON Pharmaceuticals for the treatment of patients with cancer and age-related macular degeneration pursuant to a license agreement under which Micromet has granted TRACON the worldwide rights to develop and commercialize MT293/TRC093. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.
CONTACT: Christopher Schnittker, SVP & CFO, Micromet, Inc.,
+1-240-752-1421, christopher.schnittker@micromet-inc.com; Investors, Susan
Noonan, +1-212-966-3650, susan@sanoonan.com; Media, Patricia Garrison,
+1-917-322-2567, pgarrison@rxir.com
Web site: http://www.micromet-inc.com/
